{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:49:25Z","timestamp":1790196565620,"version":"4.1.0"},"reference-count":41,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2015,2,4]]},"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background and aims<\/jats:title>\n                  <jats:p>Despite significant improvements in targeted therapies for patients with advanced gastric cancer (GC), the prognosis of those patients remains poor. This study explores the expression and clinicopathological significance of human epidermal growth factor receptor 2, 3 and 4 (HER2, HER3, HER4) in GC, in order to find more prognostic biomarkers of GC and putative targets of therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Immunohistochemistry was performed for HER2, HER3 and HER4 in 498 patients with GC using tissue microarray. Correlations between the receptor expression and clinicopathological features, as well as prognosis of the patients were statistically analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The high expression rates of HER2, HER3 and HER4 proteins in the patients were 8.6% (43\/498), 20.7% (103\/498) and 13.3% (66\/498), respectively. High expression of HER2 and HER3 was correlated with proximal GC of the cardia (p&lt;0.05). High expression of HER3 was associated with the tumour depth, tumour node metastasis (TNM) stage and lymph node metastasis (p&lt;0.05). High expression of HER4 was associated with TNM stage (p&lt;0.05) only. According to a regression model, high expression of HER3 was significantly associated with patients\u2019 poor survival (p=0.004). High expression rates of HER2, HER3 and HER4 were correlated with each other, but they were all associated merely with histologically intestinal-type adenocarcinoma of GC (p&lt;0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HER3 is correlated with the malignant biological behaviour of GC. Expression of HER3 is a significant predictor of poor survival in GC. Therefore, the development of HER3-targeted agents may provide new possibilities in the treatment of GC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jclinpath-2014-202657","type":"journal-article","created":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T22:32:54Z","timestamp":1425335574000},"page":"374-380","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival"],"prefix":"10.1136","volume":"68","author":[{"given":"Xiao Xiao","family":"He","sequence":"first","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Ming","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,3,2]]},"reference":[{"key":"2025092510110598000_68.5.374.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"2025092510110598000_68.5.374.2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.912631"},{"key":"2025092510110598000_68.5.374.3","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23262"},{"key":"2025092510110598000_68.5.374.4","doi-asserted-by":"crossref","unstructured":"Nagatsuma AK , Aizawa M , Kuwata T , et al . Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 2014 doi:10.1007\/s10120-014-0360-4. doi: 10.1007\/s10120-014-0360-4","DOI":"10.1007\/s10120-014-0360-4"},{"key":"2025092510110598000_68.5.374.5","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.13.3159"},{"key":"2025092510110598000_68.5.374.6","doi-asserted-by":"publisher","DOI":"10.2174\/1389450053765879"},{"key":"2025092510110598000_68.5.374.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0658"},{"key":"2025092510110598000_68.5.374.8","doi-asserted-by":"publisher","DOI":"10.1002\/path.1370"},{"key":"2025092510110598000_68.5.374.9","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050034"},{"key":"2025092510110598000_68.5.374.10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9771-3"},{"key":"2025092510110598000_68.5.374.11","first-page":"493","article-title":"EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases","volume":"31","author":"Wei","year":"2007","journal-title":"Int J Oncol"},{"key":"2025092510110598000_68.5.374.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.8397"},{"key":"2025092510110598000_68.5.374.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2242"},{"key":"2025092510110598000_68.5.374.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0186"},{"key":"2025092510110598000_68.5.374.15","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2013-201726"},{"key":"2025092510110598000_68.5.374.16","first-page":"76","article-title":"Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer","volume-title":"Oncology","volume":"74","author":"Matsubara","year":"2008"},{"key":"2025092510110598000_68.5.374.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1318"},{"key":"2025092510110598000_68.5.374.18","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21896"},{"key":"2025092510110598000_68.5.374.19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-524"},{"key":"2025092510110598000_68.5.374.20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3892\/ol.2013.1662","article-title":"Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: a pilot study","volume":"7","author":"Aydin","year":"2014","journal-title":"Oncol Lett"},{"key":"2025092510110598000_68.5.374.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.02.008"},{"key":"2025092510110598000_68.5.374.22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn169"},{"key":"2025092510110598000_68.5.374.23","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-011-0021-0"},{"key":"2025092510110598000_68.5.374.24","doi-asserted-by":"publisher","DOI":"10.1038\/nm0798-844"},{"key":"2025092510110598000_68.5.374.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03028.x"},{"key":"2025092510110598000_68.5.374.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1064"},{"key":"2025092510110598000_68.5.374.27","first-page":"62","article-title":"HER2 testing in gastric\/gastroesophageal junction adenocarcinomas: unique features of a familiar test","volume":"4","author":"Ross","year":"2011","journal-title":"Gastrointest Cancer Res"},{"key":"2025092510110598000_68.5.374.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094606"},{"key":"2025092510110598000_68.5.374.29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26292"},{"key":"2025092510110598000_68.5.374.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2025092510110598000_68.5.374.31","first-page":"168","article-title":"Amplification of HER-2 gene in gastric carcinoma detected by dual in situ hybridization","volume":"41","author":"Sin","year":"2012","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"2025092510110598000_68.5.374.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.6313"},{"key":"2025092510110598000_68.5.374.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-013-0236-z"},{"key":"2025092510110598000_68.5.374.34","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1609"},{"issue":"(Suppl 4)","key":"2025092510110598000_68.5.374.35","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"2025092510110598000_68.5.374.36","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-9057-1"},{"key":"2025092510110598000_68.5.374.37","first-page":"57","article-title":"HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value\u2014conclusions from 924 cases of two independent series","volume":"32","author":"Grabsch","year":"2010","journal-title":"Cell Oncol"},{"key":"2025092510110598000_68.5.374.38","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2656"},{"key":"2025092510110598000_68.5.374.39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603910"},{"key":"2025092510110598000_68.5.374.40","doi-asserted-by":"publisher","DOI":"10.1038\/nature05474"},{"key":"2025092510110598000_68.5.374.41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3892\/or.2013.2547","article-title":"Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model","volume":"30","author":"Yamashita-Kashima","year":"2013","journal-title":"Oncol Rep"}],"updated-by":[{"DOI":"10.1136\/jclinpath-2014-202657corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T00:00:00Z","timestamp":1431907200000}}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2014-202657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:11:15Z","timestamp":1758820275000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2014-202657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,2]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,4,16]]},"published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1136\/jclinpath-2014-202657"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2014-202657","relation":{"correction":[{"id-type":"doi","id":"10.1136\/jclinpath-2014-202657corr1","asserted-by":"object"}]},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,2]]}}}